# Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors

> **NCT03364400** · PHASE1 · UNKNOWN · sponsor: **Vigeo Therapeutics, Inc.** · enrollment: 116 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** VT1021

## Key facts

- **NCT ID:** NCT03364400
- **Lead sponsor:** Vigeo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-28
- **Primary completion:** 2024-01
- **Final completion:** 2024-06
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03364400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03364400, "Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03364400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*